Want to see XFOR full AI Analyst Report?
XFOR Stock Chart & Stats
$3.85
$0.09(2.34%)
At close: 4:00 PM EDT
$3.85
$0.09(2.34%)
Day’s Range― - ―
52-Week Range$2.80 - $4.83
Previous Close$3.86
Volume360.03K
Average Volume (3M)922.89K
Market Cap
$400.55M
Enterprise Value$458.70
Total Cash (Recent Filing)$207.97M
Total Debt (Recent Filing)$77.22M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Oct 29, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding99,146,740
10 Day Avg. Volume628,085
30 Day Avg. Volume922,888
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)4.82
P/FCF Ratio-1.91
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.25Price Target Upside192.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.71
Revenue Forecast (FY)$9.60M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginsStrong top-line growth and attractive gross margins indicate rising commercial traction and favorable product economics. If sustained, this combination can provide operating leverage as sales scale, although the current revenue base remains modest.
Low Leverage And Asset BaseVery low debt reduces interest and refinancing pressure while the substantial equity and asset base provide financial flexibility. This strengthens resilience during continued product investment, though ongoing losses could reduce that cushion over time.
Approved Product And Experienced GovernanceAn approved product creates a commercial foundation beyond pure clinical development, while an independent director with rare-disease and capital-markets experience can improve oversight as X4 pursues additional indications and commercialization.
Bears Say
Persistent Large Operating LossesLosses remain exceptionally large relative to revenue, showing that the current cost structure is not yet supported by the commercial base. Sustained deficits could delay self-funded growth and require continued expense control or additional capital.
Heavy Cash ConsumptionSubstantial operating and free-cash-flow deficits limit financial self-sufficiency. Unless revenue scales materially or costs decline, X4 may need additional financing to support operations, clinical programs and commercialization, creating ongoing funding risk.
Potential Equity DilutionExpanding equity incentives may support recruitment and retention in a specialized biotechnology workforce, but issuance of additional shares can dilute existing ownership. This is particularly relevant while the company remains loss-making and cash-flow negative.
X4 Pharmaceuticals News
XFOR FAQ
What was X4 Pharmaceuticals’s price range in the past 12 months?
X4 Pharmaceuticals lowest stock price was $2.80 and its highest was $4.83 in the past 12 months.
What is X4 Pharmaceuticals’s market cap?
X4 Pharmaceuticals’s market cap is $400.55M.
When is X4 Pharmaceuticals’s upcoming earnings report date?
X4 Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 66 days.
How were X4 Pharmaceuticals’s earnings last quarter?
X4 Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.176 by $0.046.
Is X4 Pharmaceuticals overvalued?
According to Wall Street analysts X4 Pharmaceuticals’s price is currently Undervalued.
Does X4 Pharmaceuticals pay dividends?
X4 Pharmaceuticals does not currently pay dividends.
What is X4 Pharmaceuticals’s EPS estimate?
X4 Pharmaceuticals’s EPS estimate is -0.18.
How many shares outstanding does X4 Pharmaceuticals have?
X4 Pharmaceuticals has 99,146,740 shares outstanding.
What happened to X4 Pharmaceuticals’s price movement after its last earnings report?
X4 Pharmaceuticals reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.176. Following the earnings report the stock price went up 11.271%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals?
Currently, no hedge funds are holding shares in XFOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
X4 Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (192.21% Upside)
$11.25 (192.21% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $356.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
140.63%
Trailing 12-Months
Company Description
X4 Pharmaceuticals
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
XFOR Stock 12 Month Forecast
Average Price Target
$11.25
▲(192.21% Upside)
Technical Analysis
Ownership Overview
0.77% Insiders
15.34% Mutual Funds
61.38% Other Institutional Investors
14.79% Public Companies and
Individual Investors